Therefore, our study may prove that M1 could be a promising therapeutic agent for fulminant hepatitis, and targeting AMPK may be useful therapeutically in the control of LPS-induced hepatotoxicity. This evidence concerns the gene PRKAA1 and Fulminant hepatitis.